In a move that would fundamentally alter the 340B program, pharmaceutical giant Johnson & Johnson (J&J) told hospitals this morning [...] …
Category: Pharma Industry
French drugmaker Sanofi has reportedly asked some hospitals for data relating to 340B purchases of a popular drug used to [...] …
Editor’s Note: With 340B-related litigation heating up in several states following the enactment of new contract pharmacy access laws this [...] …
Organon, a spinoff of pharmaceutical giant Merck with a focus on women’s health, has partially exempted covered entities in Missouri [...] …
GlaxoSmithKline (GSK) will refund covered entities that purchased certain formulations of a severe asthma treatment medication in the third quarter [...] …
340B covered entities could soon be required to share new information—including reimbursement amounts, ship to dates and ship to locations—as [...] …
Editor’s Note: With 340B-related litigation heating up in several states following the enactment of new contract pharmacy access laws this [...] …
A former Pfizer executive and current biopharmaceutical consultant took aim this week at what she called the “poorly managed” 340B [...] …
Two weeks after publishing an opinion piece that called for increased 340B program oversight and provider transparency, JAMA issued a [...] …
AbbVie will no longer offer voluntary 340B pricing on any of its orphan-designated drugs to rural referral centers (RRC), sole [...] …